Purchased shares of Class A common stock in our IPO at $16.00 per share (312,500 shares).
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
| Director | Independent | 2025 pay | Source |
|---|---|---|---|
|
Lori M. Lyons-Williams
|
Independent | $96,535 | |
|
Diego Miralles
|
Not independent | $254,156 | |
|
Stengone
|
Not independent | Not stated |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Purchased shares of Class A common stock in our IPO at $16.00 per share (312,500 shares).
Purchased shares of Class A common stock in our IPO at $16.00 per share (625,000 shares).
Purchased shares of Class A common stock in our IPO at $16.00 per share (125,000 shares).
Purchased shares of Class A common stock in our IPO at $16.00 per share (1,500,000 shares).
Purchased shares of Class A common stock in our IPO at $16.00 per share (900,000 shares).
Amended and restated Investors' Rights Agreement granting certain holders registration rights.
Exclusive worldwide license of PIPE-307 granted to J&J; we received an upfront payment.
Employed as an Associate Director; compensation comparable to similarly situated employees and approved by the compensation committee.
Legal consulting agreement with monthly retainer, later increased; terminated June 3, 2024.
Strategic, scientific and clinical consulting advisor agreement with monthly retainer, reduced later; option for 5,000 shares granted June 2024; terminated March 14, 2025.
Loading...